PolyPid (PYPD) Assets Average (2020 - 2026)
PolyPid (PYPD) posted Assets Average of $20.7 million for Q1 2026, down 15.63% sequentially from $24.6 million in Q4 2025, and down 1.43% YoY from $21.0 million in Q1 2025.
PolyPid (PYPD) Assets Average (2020 - 2026) Analysis & Trends
PolyPid has reported Assets Average for 7 years, with the latest figure at $20.7 million in Q1 2026.
- Quarterly Assets Average fell 1.43% year-over-year to $20.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.7 million (down 1.43% YoY) and the FY2025 annual result came in at $23.8 million, up 17.08% from the prior year.
- Assets Average declined to $20.7 million in Q1 2026 per PYPD's latest filing, from $24.6 million in the prior quarter.
- Over five years, Assets Average peaked at $39.9 million in Q1 2022 and troughed at $18.2 million in Q4 2023.
- A 5-year average of $26.2 million and a median of $24.6 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average plunged 46.43% in 2022, then surged 64.94% in 2025.
- Over 5 years, Assets Average stood at $27.7 million in 2022, then sank by 34.41% to $18.2 million in 2023, then grew by 23.44% to $22.4 million in 2024, then increased by 9.67% to $24.6 million in 2025, then slipped by 15.63% to $20.7 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $20.7 million, $24.6 million, and $32.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | 17.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.20 Mn |
| Mar 31, 2026 | 20.73 Mn |
| Dec 31, 2025 | 24.57 Mn |
| Sep 30, 2025 | 32.26 Mn |
| Jun 30, 2025 | 27.27 Mn |
| Mar 31, 2025 | 21.03 Mn |
| Dec 31, 2024 | 22.41 Mn |
| Sep 30, 2024 | 19.56 Mn |
| Jun 30, 2024 | 22.46 Mn |
| Mar 31, 2024 | 20.38 Mn |
| Dec 31, 2023 | 18.15 Mn |
| Sep 30, 2023 | 23.60 Mn |
| Jun 30, 2023 | 28.98 Mn |
| Mar 31, 2023 | 28.83 Mn |
| Dec 31, 2022 | 27.68 Mn |
| Sep 30, 2022 | 32.10 Mn |
| Jun 30, 2022 | 35.15 Mn |
| Mar 31, 2022 | 39.86 Mn |
| Dec 31, 2021 | 48.85 Mn |
| Sep 30, 2021 | 57.43 Mn |